Alexander Sulakvelidze is the Vice President of R&D and Chief Scientist of Intralytix. He is an internationally recognized expert in phage technology who was instrumental in securing the first ever FDA-approval for phage based food safety product in the world. He has published extensively on the subject of phage therapy including co-editing a major book about bacteriophages entitled “Bacteriophages: Biology and Applications”. He is the author of several issued and pending patents in the field of phage therapy and biocontrol. He is currently serving as an Editor-in-Chief of the scientific journal Bacteriophage and as an ad hoc Reviewer for several other journals and funding agencies. Alexander Sulakvelidze is the Vice President of R&D and Chief Scientist of Intralytix. He is an internationally recognized expert in phage technology who was instrumental in securing the first ever FDA-approval for phage based food safety product in the world. He has published extensively on the subject of phage therapy including co-editing a major book about bacteriophages entitled “Bacteriophages: Biology and Applications”. He is the author of several issued and pending patents in the field of phage therapy and biocontrol. He is currently serving as an Editor-in-Chief of the scientific journal Bacteriophage and as an ad hoc Reviewer for several other journals and funding agencies.

R&D